Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 213 articles: HTML format

Single Articles

November 2021
1. JAFFE S
   Legal challenges threaten Biden's COVID-19 vaccine rule.
   Lancet. 2021;398:1863-1864.
   PubMed    
   
   
   
2. OMER SB, Benjamin RM, Brewer NT, Buttenheim AM, et al
   Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
   Lancet. 2021 Nov 15. pii: S0140-6736(21)02507.
   PubMed     Abstract available
   
   
   
3. PAVORD S, Scully M, Lester W, Makris M, et al
   Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?
   Lancet. 2021;398:1801.
   PubMed    
   
   
   
4. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
   Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
   Lancet. 2021;398:1801-1802.
   PubMed    
   
   
   
5. LAZARUS R, Baos S, Cappel-Porter H, Carson-Stevens A, et al
   Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
   Lancet. 2021 Nov 11. pii: S0140-6736(21)02329.
   PubMed     Abstract available
   
   
   
6. ELLA R, Reddy S, Blackwelder W, Potdar V, et al
   Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
   Lancet. 2021 Nov 11. pii: S0140-6736(21)02000.
   PubMed     Abstract available
   
   
   
7. LI JX, Zhu FC
   Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.
   Lancet. 2021 Nov 11. pii: S0140-6736(21)02014.
   PubMed    
   
   
   
8. ALVES L
   Health experts welcome Brazil COVID-19 inquiry findings.
   Lancet. 2021;398:1674-1675.
   PubMed    
   
   
   
9. ORTIZ JR, Neuzil KM
   The value of vaccine programme impact monitoring during the COVID-19 pandemic.
   Lancet. 2021 Nov 3. pii: S0140-6736(21)02322.
   PubMed    
   
   
   
10. MCNAMARA LA, Wiegand RE, Burke RM, Sharma AJ, et al
    Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02226.
    PubMed     Abstract available
    
    
    
11. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    PubMed     Abstract available
    
    
    October 2021
12. BARDA N, Dagan N, Cohen C, Hernan MA, et al
    Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
    Lancet. 2021 Oct 29. pii: S0140-6736(21)02249.
    PubMed     Abstract available
    
    
    
13. GRANGE Z, Buelo A, Sullivan C, Moore E, et al
    Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
    Lancet. 2021 Oct 28. pii: S0140-6736(21)02316.
    PubMed    
    
    
    
14. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
    Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
    PubMed     Abstract available
    
    
    
15. USHER AD
    Vaccine shortages prompt changes to COVAX strategy.
    Lancet. 2021;398:1474.
    PubMed    
    
    
    
16. HILLSON K, Clemens SC, Madhi SA, Voysey M, et al
    Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
    Lancet. 2021 Oct 21. pii: S0140-6736(21)02282.
    PubMed    
    
    
    
17. SAMARASEKERA U
    Cautious optimism for malaria vaccine roll-out.
    Lancet. 2021;398:1394.
    PubMed    
    
    
    
18. SAAG MS
    Developing COVID-19 vaccine policy in increments.
    Lancet. 2021;398:1382-1383.
    PubMed    
    
    
    
19. THE LANCET
    Malaria vaccine approval: a step change for global health.
    Lancet. 2021;398:1381.
    PubMed    
    
    
    
20. PRENDECKI M, Thomson T, Clarke CL, Martin P, et al
    Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02096.
    PubMed    
    
    
    
21. TARTOF SY, Slezak JM, Fischer H, Hong V, et al
    Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02183.
    PubMed     Abstract available
    
    
    September 2021
22. THE LANCET
    COVID-19: learning as an interdependent world.
    Lancet. 2021;398:1105.
    PubMed    
    
    
    
23. SHARFSTEIN JM, Callaghan T, Carpiano RM, Sgaier SK, et al
    Uncoupling vaccination from politics: a call to action.
    Lancet. 2021 Sep 16. pii: S0140-6736(21)02099.
    PubMed    
    
    
    
24. KRAUSE PR, Fleming TR, Peto R, Longini IM, et al
    Considerations in boosting COVID-19 vaccine immune responses.
    Lancet. 2021 Sep 14. pii: S0140-6736(21)02046.
    PubMed    
    
    
    
25. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.
    PubMed    
    
    
    
26. BOSELEY S
    The race to make a COVID-19 vaccine.
    Lancet. 2021;398:832-833.
    PubMed    
    
    
    
27. JERVING S
    The long road ahead for COVID-19 vaccination in Africa.
    Lancet. 2021;398:827-828.
    PubMed    
    
    
    
28. ALIBERTI S, Dela Cruz CS, Amati F, Sotgiu G, et al
    Community-acquired pneumonia.
    Lancet. 2021;398:906-919.
    PubMed     Abstract available
    
    
    
29. ROGAWSKI MCQUADE ET, Breskin A
    Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine.
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01817.
    PubMed    
    
    
    
30. KASEJE N, Walcott D
    Global youth advocating for COVID-19 vaccines for all.
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01994.
    PubMed    
    
    
    
31. FLAXMAN A, Marchevsky NG, Jenkin D, Aboagye J, et al
    Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01699.
    PubMed     Abstract available
    
    
    August 2021
32. LANGLOIS EV, Dey T, Shah MG
    More than honour, humanitarian health-care workers need life-saving protection.
    Lancet. 2021;398:729-730.
    PubMed    
    
    
    
33. BEHRENS GM, Cossmann A, Stankov MV, Nehlmeier I, et al
    SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination.
    Lancet. 2021 Aug 17. pii: S0140-6736(21)01891.
    PubMed    
    
    
    
34. DANIELS JP
    Haiti's health woes intensify.
    Lancet. 2021;398:567.
    PubMed    
    
    
    
35. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.
    Lancet. 2021;398:577-578.
    PubMed    
    
    
    
36. CARR EJ, Wu M, Harvey R, Wall EC, et al
    Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.
    Lancet. 2021 Aug 12. pii: S0140-6736(21)01854.
    PubMed    
    
    
    
37. LLOYD-SHERLOCK P, Lasco G, McKee M, Perianayagam A, et al
    Does vaccine ageism amount to gerontocide?
    Lancet. 2021 Aug 11. pii: S0140-6736(21)01689.
    PubMed    
    
    
    
38. KALAFAT E, Magee LA, von Dadelszen P, O'Brien P, et al
    SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity.
    Lancet. 2021 Aug 11. pii: S0140-6736(21)01756.
    PubMed    
    
    
    
39. CRUMP JA, Oo WT
    Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01340.
    PubMed    
    
    
    
40. QADRI F, Khanam F, Liu X, Theiss-Nyland K, et al
    Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01124.
    PubMed     Abstract available
    
    
    
41. PRIESEMANN V, Balling R, Bauer S, Beutels P, et al
    Towards a European strategy to address the COVID-19 pandemic.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01808.
    PubMed    
    
    
    
42. LEE EJ, Lee AI
    Cerebral venous sinus thrombosis after vaccination: the UK experience.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01788.
    PubMed    
    
    
    
43. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    PubMed     Abstract available
    
    
    
44. LIU X, Shaw RH, Stuart ASV, Greenland M, et al
    Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01694.
    PubMed     Abstract available
    
    
    
45. BELDA-INIESTA C
    Optimising SARS-CoV-2 vaccination schedules.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01729.
    PubMed    
    
    
    July 2021
46. SHROTRI M, Navaratnam AMD, Nguyen V, Byrne T, et al
    Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
    Lancet. 2021;398:385-387.
    PubMed    
    
    
    
47. KAMPMANN B, Okomo U
    COVID-19 vaccines for children in LMICs: another equity issue.
    Lancet. 2021 Jul 30. pii: S0140-6736(21)01748.
    PubMed    
    
    
    
48. MAKONI M
    Social unrest disrupts South African health care.
    Lancet. 2021;398:287.
    PubMed    
    
    
    
49. REDJOUL R, Le Bouter A, Beckerich F, Fourati S, et al
    Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
    Lancet. 2021;398:298-299.
    PubMed    
    
    
    
50. THE LANCET
    COVID-19 in Africa: a lesson in solidarity.
    Lancet. 2021;398:185.
    PubMed    
    
    
    
51. DANOVARO-HOLLIDAY MC, Kretsinger K, Gacic-Dobo M
    Measuring and ensuring routine childhood vaccination coverage.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01228.
    PubMed    
    
    
    
52. CAUCHEMEZ S, Bosetti P, Kiem CT, Mouro V, et al
    Education and mental health: good reasons to vaccinate children.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01453.
    PubMed    
    
    
    
53. CAUSEY K, Fullman N, Sorensen RJD, Galles NC, et al
    Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01337.
    PubMed     Abstract available
    
    
    
54. 
    Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00984.
    PubMed     Abstract available
    
    
    
55. THE LANCET
    COVID-19 in Latin America-emergency and opportunity.
    Lancet. 2021;398:93.
    PubMed    
    
    
    
56. TANRIOVER MD, Doganay HL, Akova M, Guner HR, et al
    Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Lancet. 2021 Jul 8. pii: S0140-6736(21)01429.
    PubMed     Abstract available
    
    
    
57. GURDASANI D, Drury J, Greenhalgh T, Griffin S, et al
    Mass infection is not an option: we must do more to protect our young.
    Lancet. 2021 Jul 7. pii: S0140-6736(21)01589.
    PubMed    
    
    
    June 2021
58. WALL EC, Wu M, Harvey R, Kelly G, et al
    AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
    Lancet. 2021 Jun 28. pii: S0140-6736(21)01462.
    PubMed    
    
    
    
59. SMITH MJ
    What constitutes success in the roll-out of COVID-19 vaccines?
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01244.
    PubMed    
    
    
    
60. DUARTE-SALLES T, Prieto-Alhambra D
    Heterologous vaccine regimens against COVID-19.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01442.
    PubMed    
    
    
    
61. BOROBIA AM, Carcas AJ, Perez-Olmeda M, Castano L, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01420.
    PubMed     Abstract available
    
    
    
62. THE LANCET
    Protecting refugees during the COVID-19 pandemic.
    Lancet. 2021;397:2309.
    PubMed    
    
    
    
63. ABECASSIS A
    Five priorities for universal COVID-19 vaccination.
    Lancet. 2021 Jun 17. pii: S0140-6736(21)01371.
    PubMed    
    
    
    
64. SHEIKH A, McMenamin J, Taylor B, Robertson C, et al
    SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
    Lancet. 2021 Jun 14. pii: S0140-6736(21)01358.
    PubMed    
    
    
    
65. GAYTHORPE KAM, Toor J, Echeverria-Londono S, Li X, et al
    Vaccines can save children with non-preventable diseases - Authors' reply.
    Lancet. 2021;397:2251.
    PubMed    
    
    
    
66. SAHA S, Saha SK
    Vaccines can save children with non-preventable diseases.
    Lancet. 2021;397:2250.
    PubMed    
    
    
    
67. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    COVID-19 vaccine efficacy data: solid enough to delay second dose? - Authors' reply.
    Lancet. 2021;397:2249-2250.
    PubMed    
    
    
    
68. ROBERTSON JFR, Sewell HF
    COVID-19 vaccine efficacy data: solid enough to delay second dose?
    Lancet. 2021;397:2248-2249.
    PubMed    
    
    
    
69. VOYSEY M, Pollard AJ
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.
    Lancet. 2021;397:2248.
    PubMed    
    
    
    
70. MCQUADE ETR, Platts-Mills JA
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates.
    Lancet. 2021;397:2247-2248.
    PubMed    
    
    
    
71. NASSER A, Zakham F
    A strategy for SARS-CoV-2 vaccination in Yemen.
    Lancet. 2021;397:2247.
    PubMed    
    
    
    
72. GUETL K, Gary T, Raggam RB, Schmid J, et al
    SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban.
    Lancet. 2021 Jun 11. pii: S0140-6736(21)01238.
    PubMed    
    
    
    
73. BOLLYKY TJ, Murray CJL, Reiner RC Jr
    Epidemiology, not geopolitics, should guide COVID-19 vaccine donations.
    Lancet. 2021 Jun 8. pii: S0140-6736(21)01323.
    PubMed    
    
    
    
74. KUMAR A, Bernasconi V, Manak M, de Almeida Aranha AP, et al
    The CEPI centralised laboratory network: supporting COVID-19 vaccine development.
    Lancet. 2021;397:2148-2149.
    PubMed    
    
    
    
75. WALL EC, Wu M, Harvey R, Kelly G, et al
    Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01290.
    PubMed    
    
    
    
76. NNAJI CA, Ndwandwe D, Lesosky M, Mahomed H, et al
    Tackling missed opportunities for vaccination in a new era of immunisation.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01226.
    PubMed    
    
    
    
77. KOSAKA M, Hashimoto T, Ozaki A, Tanimoto T, et al
    Delayed COVID-19 vaccine roll-out in Japan.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01220.
    PubMed    
    
    
    
78. FORMAN R, Jit M, Mossialos E
    Divergent vaccination policies could fuel mistrust and hesitancy.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)01106.
    PubMed    
    
    
    May 2021
79. MAKONI M
    Africa's need for more COVID-19 clinical trials.
    Lancet. 2021;397:2037.
    PubMed    
    
    
    
80. JAWAD NK, Taweeleh LA, Elharake JA, Khamis N, et al
    Refugee access to COVID-19 vaccines in Lebanon.
    Lancet. 2021;397:1884.
    PubMed    
    
    
    
81. ZAROCOSTAS J
    What next for a COVID-19 intellectual property waiver?
    Lancet. 2021;397:1871-1872.
    PubMed    
    
    
    
82. LOYO ESL, Gonzalez MJ, Esparza J
    Venezuela is collapsing without COVID-19 vaccines.
    Lancet. 2021;397:1806.
    PubMed    
    
    
    
83. WATSON SI
    Global COVID-19 vaccine roll-out: time to randomise vaccine allocation?
    Lancet. 2021;397:1804-1805.
    PubMed    
    
    
    
84. TORRES I, Lopez-Cevallos D, Artaza O, Profeta B, et al
    Vaccine scarcity in LMICs is a failure of global solidarity and multilateral instruments.
    Lancet. 2021;397:1804.
    PubMed    
    
    
    
85. HOUSTON AR, Murthy S
    Canada is no global health leader on COVID-19 vaccine equity.
    Lancet. 2021;397:1803.
    PubMed    
    
    
    
86. HOLT E
    Serbia begins paying citizens to receive a COVID-19 vaccine.
    Lancet. 2021;397:1793.
    PubMed    
    
    
    
87. GENC K
    COVID-19 in Turkey: a nation on edge.
    Lancet. 2021;397:1794-1796.
    PubMed    
    
    
    
88. JHA P, Jamison DT, Watkins DA, Bell J, et al
    A global compact to counter vaccine nationalism.
    Lancet. 2021 May 14. pii: S0140-6736(21)01105.
    PubMed    
    
    
    
89. KUPPALLI K, Gala P, Cherabuddi K, Kalantri SP, et al
    India's COVID-19 crisis: a call for international action.
    Lancet. 2021 May 14. pii: S0140-6736(21)01121.
    PubMed    
    
    
    
90. SHAW RH, Stuart A, Greenland M, Liu X, et al
    Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Lancet. 2021 May 12. pii: S0140-6736(21)01115.
    PubMed    
    
    
    
91. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV
    Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply.
    Lancet. 2021 May 12. pii: S0140-6736(21)00894.
    PubMed    
    
    
    
92. MOORTHY V, Binka F
    R21/Matrix-M: a second malaria vaccine?
    Lancet. 2021 May 5. pii: S0140-6736(21)01065.
    PubMed    
    
    
    
93. DATOO MS, Natama MH, Some A, Traore O, et al
    Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
    Lancet. 2021 May 5. pii: S0140-6736(21)00943.
    PubMed     Abstract available
    
    
    
94. HAAS EJ, Angulo FJ, McLaughlin JM, Anis E, et al
    Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Lancet. 2021 May 5. pii: S0140-6736(21)00947.
    PubMed     Abstract available
    
    
    
95. LESHEM E, Wilder-Smith A
    COVID-19 vaccine impact in Israel and a way out of the pandemic.
    Lancet. 2021 May 5. pii: S0140-6736(21)01018.
    PubMed    
    
    
    
96. BHUYAN A
    Experts criticise India's complacency over COVID-19.
    Lancet. 2021;397:1611-1612.
    PubMed    
    
    
    April 2021
97. BURKI T
    Statelessness in the COVID-19 pandemic.
    Lancet. 2021;397:1529-1530.
    PubMed    
    
    
    
98. THE LANCET
    2021: the beginning of a new era of immunisations?
    Lancet. 2021;397:1519.
    PubMed    
    
    
    
99. HALL VJ, Foulkes S, Saei A, Andrews N, et al
    COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00790.
    PubMed     Abstract available
    
    
    
100. LESHEM E, Lopman BA
     Population immunity and vaccine protection against infection.
     Lancet. 2021 Apr 23. pii: S0140-6736(21)00870.
     PubMed    
     
     
     
101. DEAN N
     Hospital admissions due to COVID-19 in Scotland after one dose of vaccine.
     Lancet. 2021 Apr 23. pii: S0140-6736(21)00765.
     PubMed    
     
     
     
102. VASILEIOU E, Simpson CR, Shi T, Kerr S, et al
     Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
     Lancet. 2021 Apr 23. pii: S0140-6736(21)00677.
     PubMed     Abstract available
     
     
     
103. KHAN MS, Ali SAM, Adelaine A, Karan A, et al
     Rethinking vaccine hesitancy among minority groups.
     Lancet. 2021 Apr 21. pii: S0140-6736(21)00938.
     PubMed    
     
     
     
104. ALVES L
     Brazilian ICUs short of drugs and beds amid COVID-19 surge.
     Lancet. 2021;397:1431-1432.
     PubMed    
     
     
     
105. BAYAS A, Menacher M, Christ M, Behrens L, et al
     Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
     Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
     PubMed    
     
     
     
106. MUSTER V, Gary T, Raggam RB, WOlfler A, et al
     Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination.
     Lancet. 2021 Apr 14. pii: S0140-6736(21)00871.
     PubMed    
     
     
     
107. MFINANGA SG, Mnyambwa NP, Minja DT, Ntinginya NE, et al
     Tanzania's position on the COVID-19 pandemic.
     Lancet. 2021 Apr 14. pii: S0140-6736(21)00678.
     PubMed    
     
     
     
108. CAPUA I, Giaquinto C
     The unsung virtue of thermostability.
     Lancet. 2021;397:1346.
     PubMed    
     
     
     
109. ALI SN, Hanif W, Patel K, Khunti K, et al
     Ramadan and COVID-19 vaccine hesitancy-a call for action.
     Lancet. 2021 Apr 7. pii: S0140-6736(21)00779.
     PubMed    
     
     
     
110. D'SOUZA RS, Wolfe I
     COVID-19 vaccines in high-risk ethnic groups.
     Lancet. 2021 Apr 1. pii: S0140-6736(21)00624.
     PubMed    
     
     
     March 2021
111. EMARY KRW, Golubchik T, Aley PK, Ariani CV, et al
     Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
     Lancet. 2021 Mar 30. pii: S0140-6736(21)00628.
     PubMed     Abstract available
     
     
     
112. OSTERGAARD SD, Schmidt M, Horvath-Puho E, Thomsen RW, et al
     Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
     Lancet. 2021 Mar 30. pii: S0140-6736(21)00762.
     PubMed    
     
     
     
113. SANDERS RW, de Jong MD
     Pandemic moves and countermoves: vaccines and viral variants.
     Lancet. 2021 Mar 30. pii: S0140-6736(21)00730.
     PubMed    
     
     
     
114. MYLAN S, Hardman C
     COVID-19, cults, and the anti-vax movement.
     Lancet. 2021;397:1181.
     PubMed    
     
     
     
115. USHER AD
     Uncertainties over EU COVID-19 vaccine sharing scheme.
     Lancet. 2021;397:1171.
     PubMed    
     
     
     
116. KLUGE H, McKee M
     COVID-19 vaccines for the European region: an unprecedented challenge.
     Lancet. 2021 Mar 25. pii: S0140-6736(21)00709.
     PubMed    
     
     
     
117. 
     Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights.
     Lancet. 2021 Mar 24. pii: S0140-6736(21)00708.
     PubMed    
     
     
     
118. CHANDAN JS, Chandan JK
     Considering gender-based violence in vaccine prioritisation strategies.
     Lancet. 2021 Mar 24. pii: S0140-6736(21)00532.
     PubMed    
     
     
     
119. KRISTIANSEN PA, Page M, Bernasconi V, Mattiuzzo G, et al
     WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
     Lancet. 2021 Mar 23. pii: S0140-6736(21)00527.
     PubMed    
     
     
     
120. KARIM SSA
     Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.
     Lancet. 2021 Mar 22. pii: S0140-6736(21)00468.
     PubMed    
     
     
     
121. MUNDT AP
     Assessing government responsibility for COVID-19 deaths.
     Lancet. 2021 Mar 22. pii: S0140-6736(21)00529.
     PubMed    
     
     
     
122. SAAH AJ, Munoz N
     Control vaccine formulation - Authors' reply.
     Lancet. 2021;397:1062.
     PubMed    
     
     
     
123. DOSHI P, Hong K, Jefferson T, Jones M, et al
     Control vaccine formulation.
     Lancet. 2021;397:1061-1062.
     PubMed    
     
     
     
124. JAFFE S
     Biden's first legislative victory: $1.9 trillion for COVID-19.
     Lancet. 2021;397:1047-1048.
     PubMed    
     
     
     
125. THE LANCET
     Myanmar's democracy and health on life support.
     Lancet. 2021;397:1035.
     PubMed    
     
     
     
126. BOZORGMEHR K, Jahn R, Stuckler D, McKee M, et al
     Free licensing of vaccines to end the COVID-19 crisis.
     Lancet. 2021 Mar 18. pii: S0140-6736(21)00467.
     PubMed    
     
     
     
127. KRIEGER N, Waterman PD, Chen JT, Testa C, et al
     Missing again: US racial and ethnic data for COVID-19 vaccination.
     Lancet. 2021 Mar 17. pii: S0140-6736(21)00465.
     PubMed    
     
     
     
128. HOLT E
     Countries split from EU on COVID-19 vaccines.
     Lancet. 2021;397:958.
     PubMed    
     
     
     
129. THE LANCET
     Access to COVID-19 vaccines: looking beyond COVAX.
     Lancet. 2021;397:941.
     PubMed    
     
     
     
130. DEVI S
     Health in Syria: a decade of conflict.
     Lancet. 2021;397:955-956.
     PubMed    
     
     
     
131. STEINBERG J, Thomas A, Iravani A
     (18)Fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.
     Lancet. 2021 Mar 8. pii: S0140-6736(21)00464.
     PubMed    
     
     
     
132. SAMARASEKERA U
     Robin Shattock: novel vaccine developer.
     Lancet. 2021;397:870.
     PubMed    
     
     
     
133. HUNG IFN, Poland GA
     Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.
     Lancet. 2021;397:854-855.
     PubMed    
     
     
     
134. VIJAYASINGHAM L, Bischof E, Wolfe J
     Sex-disaggregated data in COVID-19 vaccine trials.
     Lancet. 2021 Mar 5. pii: S0140-6736(21)00384.
     PubMed    
     
     
     February 2021
135. BATNIJI R
     Historical evidence to inform COVID-19 vaccine mandates.
     Lancet. 2021;397:791.
     PubMed    
     
     
     
136. CHAUVIN L
     Peruvian COVID-19 vaccine scandal spreads.
     Lancet. 2021;397:783.
     PubMed    
     
     
     
137. ZAROCOSTAS J
     New WTO leader faces COVID-19 challenges.
     Lancet. 2021;397:782.
     PubMed    
     
     
     
138. ADEPOJU P
     Ebola returns to Guinea and DR Congo.
     Lancet. 2021;397:781.
     PubMed    
     
     
     
139. PRENDECKI M, Clarke C, Brown J, Cox A, et al
     Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
     Lancet. 2021 Feb 25. pii: S0140-6736(21)00502.
     PubMed    
     
     
     
140. MANISTY C, Otter AD, Treibel TA, McKnight A, et al
     Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
     Lancet. 2021 Feb 25. pii: S0140-6736(21)00501.
     PubMed    
     
     
     
141. 
     Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
     Lancet. 2021 Feb 24. pii: S0140-6736(21)00372.
     PubMed    
     
     
     
142. SIVA N
     Severe mental illness: reassessing COVID-19 vaccine priorities.
     Lancet. 2021;397:657.
     PubMed    
     
     
     
143. HYDE R
     von der Leyen admits to COVID-19 vaccine failures.
     Lancet. 2021;397:655-656.
     PubMed    
     
     
     
144. VOYSEY M, Costa Clemens SA, Madhi SA, Weckx LY, et al
     Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
     Lancet. 2021 Feb 19. pii: S0140-6736(21)00432.
     PubMed     Abstract available
     
     
     
145. SISA I, Noblecilla E, Orozco F
     Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
     Lancet. 2021 Feb 19. pii: S0140-6736(21)00357.
     PubMed    
     
     
     
146. ROBERTSON JFR, Sewell HF, Stewart M
     Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
     Lancet. 2021 Feb 19. pii: S0140-6736(21)00455.
     PubMed    
     
     
     
147. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
     Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
     Lancet. 2021 Feb 18. pii: S0140-6736(21)00448.
     PubMed    
     
     
     
148. SKEGG D, Gluckman P, Boulton G, Hackmann H, et al
     Future scenarios for the COVID-19 pandemic.
     Lancet. 2021 Feb 16. pii: S0140-6736(21)00424.
     PubMed    
     
     
     
149. MAKONI M
     Tanzania refuses COVID-19 vaccines.
     Lancet. 2021;397:566.
     PubMed    
     
     
     
150. THE LANCET
     Improving prisoner health for stronger public health.
     Lancet. 2021;397:555.
     PubMed    
     
     
     
151. WOUTERS OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, et al
     Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
     Lancet. 2021 Feb 12. pii: S0140-6736(21)00306.
     PubMed     Abstract available
     
     
     
152. 
     Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission.
     Lancet. 2021 Feb 12. pii: S0140-6736(21)00388.
     PubMed    
     
     
     
153. FONTANET A, Autran B, Lina B, Kieny MP, et al
     SARS-CoV-2 variants and ending the COVID-19 pandemic.
     Lancet. 2021 Feb 11. pii: S0140-6736(21)00370.
     PubMed    
     
     
     
154. MARTIN S, Arawi T
     Ensure Palestinians have access to COVID-19 vaccines.
     Lancet. 2021 Feb 9. pii: S0140-6736(21)00190.
     PubMed    
     
     
     
155. BEHRENS RH, Patel V
     Avoiding shoulder injury from intramuscular vaccines.
     Lancet. 2021;397:471.
     PubMed    
     
     
     
156. WARRELL MJ
     Time to revise the strategy for Gavi funding of rabies vaccine?
     Lancet. 2021;397:471-472.
     PubMed    
     
     
     
157. LANE R
     Tahmeed Ahmed: new leader of icddr,b.
     Lancet. 2021;397:463.
     PubMed    
     
     
     
158. LOIZIDES U, Adisa A, de la Rica Manjavacas AL, Robertson JS, et al
     WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.
     Lancet. 2021 Feb 4. pii: S0140-6736(21)00099.
     PubMed    
     
     
     
159. MEREWOOD A, Bode L, Davanzo R, Perez-Escamilla R, et al
     Breastfeed or be vaccinated-an unreasonable default recommendation.
     Lancet. 2021 Feb 4. pii: S0140-6736(21)00197.
     PubMed    
     
     
     
160. CLARFIELD AM, Skorecki K, Manor O, Glick S, et al
     A COVID-19 jab in the right direction.
     Lancet. 2021 Feb 4. pii: S0140-6736(21)00310.
     PubMed    
     
     
     
161. JONES I, Roy P
     Sputnik V COVID-19 vaccine candidate appears safe and effective.
     Lancet. 2021 Feb 2. pii: S0140-6736(21)00191.
     PubMed    
     
     
     
162. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, et al
     Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
     Lancet. 2021 Feb 2. pii: S0140-6736(21)00234.
     PubMed     Abstract available
     
     
     
163. FRIESEN P, Caplan AL, Miller JE
     COVID-19 vaccine research and the trouble with clinical equipoise.
     Lancet. 2021 Feb 1. pii: S0140-6736(21)00198.
     PubMed    
     
     
     January 2021
164. LI X, Mukandavire C, Cucunuba ZM, Echeverria Londono S, et al
     Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
     Lancet. 2021;397:398-408.
     PubMed     Abstract available
     
     
     
165. DANIELS JP
     Health experts slam Bolsonaro's vaccine comments.
     Lancet. 2021;397:361.
     PubMed    
     
     
     
166. COHEN AL, Patel MK, Cherian T
     Vaccines work: a reason for celebration and renewed commitment.
     Lancet. 2021;397:351-353.
     PubMed    
     
     
     
167. THE LANCET
     Health and care workers are owed a better future.
     Lancet. 2021;397:347.
     PubMed    
     
     
     
168. BLAKNEY AK, McKay PF
     Next-generation COVID-19 vaccines: here come the proteins.
     Lancet. 2021 Jan 29. pii: S0140-6736(21)00258.
     PubMed    
     
     
     
169. RICHMOND P, Hatchuel L, Dong M, Ma B, et al
     Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
     Lancet. 2021 Jan 29. pii: S0140-6736(21)00241.
     PubMed     Abstract available
     
     
     
170. 
     Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.
     Lancet. 2021 Jan 28. pii: S0140-6736(21)00242.
     PubMed    
     
     
     
171. WATT G, Giacaman R, Zurayk H, Bjertness E, et al
     COVID-19 vaccines for Palestinians.
     Lancet. 2021 Jan 28. pii: S0140-6736(21)00185.
     PubMed    
     
     
     
172. BARDAJI A, Sevene E, Cutland C, Menendez C, et al
     The need for a global COVID-19 maternal immunisation research plan.
     Lancet. 2021 Jan 25. pii: S0140-6736(21)00146.
     PubMed    
     
     
     
173. BHUYAN A
     India begins COVID-19 vaccination amid trial allegations.
     Lancet. 2021;397:264.
     PubMed    
     
     
     
174. MAKONI M
     South Africa responds to new SARS-CoV-2 variant.
     Lancet. 2021;397:267.
     PubMed    
     
     
     
175. USHER AD
     CEPI criticised for lack of transparency.
     Lancet. 2021;397:265-266.
     PubMed    
     
     
     
176. CAVALERI M, Enzmann H, Straus S, Cooke E, et al
     The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
     Lancet. 2021 Jan 13. pii: S0140-6736(21)00085.
     PubMed    
     
     
     
177. STAPLES JE, Alvarez AR
     Public health role for fractional dosage of yellow fever vaccine.
     Lancet. 2021;397:76-77.
     PubMed    
     
     
     
178. JUAN-GINER A, Kimathi D, Grantz KH, Hamaluba M, et al
     Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
     Lancet. 2021;397:119-127.
     PubMed     Abstract available
     
     
     
179. GOSTIN LO, Shalala DE, Hamburg MA, Bloom BR, et al
     A global health action agenda for the Biden administration.
     Lancet. 2021;397:5-8.
     PubMed    
     
     
     December 2020
180. HARMAN S, Herten-Crabb A, Morgan R, Smith J, et al
     COVID-19 vaccines and women's security.
     Lancet. 2020 Dec 22. pii: S0140-6736(20)32727.
     PubMed    
     
     
     
181. CLAESON M, Hanson S
     COVID-19 and the Swedish enigma.
     Lancet. 2020 Dec 22. pii: S0140-6736(20)32750.
     PubMed    
     
     
     
182. SIVA N
     Experts call to include prisons in COVID-19 vaccine plans.
     Lancet. 2020;396:1870.
     PubMed    
     
     
     
183. BURGESS RA, Osborne RH, Yongabi KA, Greenhalgh T, et al
     The COVID-19 vaccines rush: participatory community engagement matters more than ever.
     Lancet. 2020 Dec 10. pii: S0140-6736(20)32642.
     PubMed    
     
     
     
184. DE COSTER I, Leroux-Roels I, Bandyopadhyay AS, Gast C, et al
     Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
     Lancet. 2020 Dec 9. pii: S0140-6736(20)32541.
     PubMed     Abstract available
     
     
     
185. SAEZ-LLORENS X, Bandyopadhyay AS, Gast C, Leon T, et al
     Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
     Lancet. 2020 Dec 9. pii: S0140-6736(20)32540.
     PubMed     Abstract available
     
     
     
186. THOMPSON KM
     Poliovirus vaccine options: another step forward.
     Lancet. 2020 Dec 9. pii: S0140-6736(20)32629.
     PubMed    
     
     
     
187. ARYEETEY E, Engebretsen E, Gornitzka A, Maassen P, et al
     A step backwards in the fight against global vaccine inequities.
     Lancet. 2020 Dec 9. pii: S0140-6736(20)32596.
     PubMed    
     
     
     
188. KNOLL MD, Wonodi C
     Oxford-AstraZeneca COVID-19 vaccine efficacy.
     Lancet. 2020 Dec 8. pii: S0140-6736(20)32623.
     PubMed    
     
     
     
189. VOYSEY M, Clemens SAC, Madhi SA, Weckx LY, et al
     Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
     Lancet. 2020 Dec 8. pii: S0140-6736(20)32661.
     PubMed     Abstract available
     
     
     
190. USHER AD
     South Africa and India push for COVID-19 patents ban.
     Lancet. 2020;396:1790-1791.
     PubMed    
     
     
     
191. THE LANCET
     An African plan to control COVID-19 is urgently needed.
     Lancet. 2020;396:1777.
     PubMed    
     
     
     
192. MULHOLLAND K, Kretsinger K, Wondwossen L, Crowcroft N, et al
     Action needed now to prevent further increases in measles and measles deaths in the coming years.
     Lancet. 2020;396:1782-1784.
     PubMed    
     
     
     November 2020
193. THE LANCET
     COVID-19 vaccines: no time for complacency.
     Lancet. 2020;396:1607.
     PubMed    
     
     
     
194. RAMASAMY MN, Minassian AM, Ewer KJ, Flaxman AL, et al
     Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
     Lancet. 2020 Nov 18. pii: S0140-6736(20)32466.
     PubMed     Abstract available
     
     
     
195. ANDREW MK, McElhaney JE
     Age and frailty in COVID-19 vaccine development.
     Lancet. 2020 Nov 18. pii: S0140-6736(20)32481.
     PubMed    
     
     
     
196. VOYSEY M, Pollard AJ
     ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
     Lancet. 2020;396:1486-1487.
     PubMed    
     
     
     
197. LODGE A
     ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
     Lancet. 2020;396:1486.
     PubMed    
     
     
     
198. CHAUHAN A, Agarwal A, Jaiswal N, Singh M, et al
     ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
     Lancet. 2020;396:1485-1486.
     PubMed    
     
     
     
199. HORTON R
     Offline: Managing the COVID-19 vaccine infodemic.
     Lancet. 2020;396:1474.
     PubMed    
     
     
     
200. SMITH MJ, Ujewe S, Katz R, Upshur REG, et al
     Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.
     Lancet. 2020 Nov 5. pii: S0140-6736(20)32337.
     PubMed    
     
     
     
201. ANDERSON RM, Vegvari C, Truscott J, Collyer BS, et al
     Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.
     Lancet. 2020 Nov 4. pii: S0140-6736(20)32318.
     PubMed    
     
     
     October 2020
202. HASSAN-SMITH Z, Hanif W, Khunti K
     Who should be prioritised for COVID-19 vaccines?
     Lancet. 2020 Oct 27. pii: S0140-6736(20)32224.
     PubMed    
     
     
     
203. BINGHAM K
     The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world.
     Lancet. 2020 Oct 27. pii: S0140-6736(20)32175.
     PubMed    
     
     
     
204. KRAUSE PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM, et al
     Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.
     Lancet. 2020 Oct 27. pii: S0140-6736(20)32259.
     PubMed    
     
     
     
205. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
     Use of adenovirus type-5 vectored vaccines: a cautionary tale.
     Lancet. 2020 Oct 19. pii: S0140-6736(20)32156.
     PubMed    
     
     
     
206. WARD BJ, Makarkov A, Seguin A, Pillet S, et al
     Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (>/=65 years): two multicentre, randomised phase 3 trials.
     Lancet. 2020 Oct 13. pii: S0140-6736(20)32014.
     PubMed     Abstract available
     
     
     
207. POLAND GA, Ovsyannikova IG, Kennedy RB
     SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
     Lancet. 2020 Oct 13. pii: S0140-6736(20)32137.
     PubMed     Abstract available
     
     
     
208. TREGONING JS
     First human efficacy study of a plant-derived influenza vaccine.
     Lancet. 2020 Oct 13. pii: S0140-6736(20)32010.
     PubMed    
     
     
     
209. MCMAHON JH, Hoy JF, Kamarulzaman A, Bekker LG, et al
     Leveraging the advances in HIV for COVID-19.
     Lancet. 2020;396:943-944.
     PubMed    
     
     
     September 2020
210. LOGUNOV DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV, et al
     Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.
     Lancet. 2020 Sep 21. pii: S0140-6736(20)31970.
     PubMed    
     
     
     
211. PEIRIS M, Leung GM
     What can we expect from first-generation COVID-19 vaccines?
     Lancet. 2020 Sep 21. pii: S0140-6736(20)31976.
     PubMed    
     
     
     
212. BUCCI E, Andreev K, Bjorkman A, Calogero RA, et al
     Safety and efficacy of the Russian COVID-19 vaccine: more information needed.
     Lancet. 2020 Sep 21. pii: S0140-6736(20)31960.
     PubMed    
     
     
     
213. THE LANCET
     Global collaboration for health: rhetoric versus reality.
     Lancet. 2020;396:735.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: